inotropic agent
Recently Published Documents


TOTAL DOCUMENTS

194
(FIVE YEARS 0)

H-INDEX

24
(FIVE YEARS 0)

2020 ◽  
Vol 115 (4) ◽  
Author(s):  
Camilla Schinner ◽  
Silvana Olivares-Florez ◽  
Angela Schlipp ◽  
Sebastian Trenz ◽  
Manouk Feinendegen ◽  
...  


2019 ◽  
Vol 33 (S1) ◽  
Author(s):  
Camilla Schinner ◽  
Silvana Olivares‐Florez ◽  
Angela Schlipp ◽  
Sebastian Trenz ◽  
Manouk Feinendegen ◽  
...  


2018 ◽  
Vol 434 ◽  
pp. 81-90 ◽  
Author(s):  
Sung-Han Hsiao ◽  
Megumi Murakami ◽  
Ni Yeh ◽  
Yan-Qing Li ◽  
Tai-Ho Hung ◽  
...  




2018 ◽  
Vol 133 ◽  
pp. 132-140 ◽  
Author(s):  
Alexandre Bossu ◽  
Amée Kostense ◽  
Henriette D.M. Beekman ◽  
Marien J.C. Houtman ◽  
Marcel A.G. van der Heyden ◽  
...  


2018 ◽  
Vol 62 (4) ◽  
pp. 420-450 ◽  
Author(s):  
M. H. Møller ◽  
A. Granholm ◽  
E. Junttila ◽  
M. Haney ◽  
A. Oscarsson-Tibblin ◽  
...  


2017 ◽  
Vol 23 (10) ◽  
pp. S63
Author(s):  
Wataru Fujimoto ◽  
Syogo Oishi ◽  
Akira Shimane ◽  
Yasuyo Taniguchi ◽  
Yoshinori Yasaka ◽  
...  


2016 ◽  
Vol 94 (10) ◽  
pp. 1033-1039 ◽  
Author(s):  
Péter Nánási ◽  
Krisztina Váczi ◽  
Zoltán Papp

Heart failure became a leading cause of mortality in the past few decades with a progressively increasing prevalence. Its current therapy is restricted largely to the suppression of the sympathetic activity and the renin–angiotensin system in combination with diuretics. This restrictive strategy is due to the potential long-term adverse effects of inotropic agents despite their effective influence on cardiac function when employed for short durations. Positive inotropes include inhibitors of the Na+/K+ pump, β-receptor agonists, and phosphodiesterase inhibitors. Theoretically, Ca2+ sensitizers may also increase cardiac contractility without resulting in Ca2+ overload; nevertheless, their mechanism of action is frequently complicated by other pleiotropic effects. Recently, a new positive inotropic agent, the myosin activator omecamtiv mecarbil, has been developed. Omecamtiv mecarbil binds directly to β-myosin heavy chain and enhances cardiac contractility by increasing the number of the active force-generating cross-bridges, presumably without major off-target effects. This review focuses on recent in vivo and in vitro results obtained with omecamtiv mecarbil, and discusses its mechanism of action at a molecular level. Based on clinical data, omecamtiv mecarbil is a promising new tool in the treatment of systolic heart failure.



2016 ◽  
Vol 2016 ◽  
pp. 1-15 ◽  
Author(s):  
Mai E. Shoman ◽  
Omar M. Aly

Nitroxyl (HNO), the one-electron reduced form of nitric oxide (NO), shows a distinct chemical and biological profile from that of NO. HNO is currently being viewed as a vasodilator and positive inotropic agent that can be used as a potential treatment for heart failure. The ability of HNO to react with thiols and thiol containing proteins is largely used to explain the possible biological actions of HNO. Herein, we summarize different aspects related to HNO including HNO donors, chemistry, biology, and methods used for its detection.



Engineering ◽  
2015 ◽  
Vol 1 (4) ◽  
pp. 401-404 ◽  
Author(s):  
Ye Tian ◽  
Nazareno Paolocci ◽  
Wei Dong Gao


Sign in / Sign up

Export Citation Format

Share Document